Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215006, China.
Department of Ultrasound, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
World J Surg Oncol. 2020 Jul 6;18(1):157. doi: 10.1186/s12957-020-01939-z.
This study aimed to assess the correlation of katanin P60 expression with clinical characteristics and survival profiles of surgical non-small cell lung cancer (NSCLC) patients.
Two hundred and sixty-five primary NSCLC patients treated by surgical resection were retrospectively viewed. The expression of katanin P60 in the tumor specimen was detected by the immunohistochemical (IHC) staining assay. Preoperative clinical data were collected from patients' medical records, and survival data were extracted from follow-up records.
There were 127 (47.9%) and 138 (52.1%) patients with katanin P60-low expression and -high expression, respectively; in addition, patients presenting katanin P60-high+, -high++, and -high+++ expression were 62 (23.4%), 63 (23.8%), and 13 (4.9%), respectively. Katanin P60 expression was correlated with lymph node (LYN) metastasis and advanced TNM stage but not pathological grade, tumor size, carcinoembryonic antigen (CEA) level or other non-tumor features in NSCLC patients. Regarding survival profiles, disease-free survival (DFS) and overall survival (OS) were both the lowest in katanin P60-high+++ expression patients, followed with katanin P60-high++ patients, katanin P60-high+ patients, and the highest in katanin P60-low expression patients. Further analysis illustrated that katanin P60-high expression was an independent predictive factor for unfavorable DFS and OS in NSCLC patients.
Katanin P60 presents potential as a biomarker for lymph node metastasis and prognosis in NSCLC patients.
本研究旨在评估 katanin P60 表达与手术治疗非小细胞肺癌（NSCLC）患者临床特征和生存状况的相关性。
回顾性观察 265 例接受手术治疗的原发性 NSCLC 患者。采用免疫组织化学（IHC）染色法检测肿瘤标本中 katanin P60 的表达。从患者病历中收集术前临床数据，并从随访记录中提取生存数据。
katanin P60 低表达和高表达的患者分别为 127 例（47.9%）和 138 例（52.1%）；此外，katanin P60 高表达+、高表达++和高表达+++的患者分别为 62 例（23.4%）、63 例（23.8%）和 13 例（4.9%）。katanin P60 表达与淋巴结（LYN）转移和晚期 TNM 分期相关，但与 NSCLC 患者的病理分级、肿瘤大小、癌胚抗原（CEA）水平或其他非肿瘤特征无关。在生存状况方面，katanin P60 高表达+++患者的无病生存率（DFS）和总生存率（OS）均最低，其次是 katanin P60 高表达++患者、katanin P60 高表达+患者，katanin P60 低表达患者的生存率最高。进一步分析表明，katanin P60 高表达是 NSCLC 患者DFS 和 OS 不良的独立预测因素。
kataanin P60 有望成为 NSCLC 患者淋巴结转移和预后的生物标志物。
